Kristen Kozey Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 77 Kozey Rd, Eastford, CT 06242 Phone: 860-933-8587 |
Ms. Signe Adam, LCSW Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 289 Chaplin Rd, Eastford, CT 06242 Phone: 860-974-0036 Fax: 860-974-0036 |
Mr. Robert F Adam, LCSW Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 289 Chaplin Rd, Eastford, CT 06242 Phone: 860-974-0036 |
Meg Bishop, LCSW Clinical Social Worker Medicare: Medicare Enrolled Practice Location: 16 Trepal Dr, Eastford, CT 06242 Phone: 860-214-6883 Fax: 860-429-2949 |
News Archive
The Association of Rehabilitation Nurses is pleased to announce the availability of the eagerly awaited The Specialty Practice of Rehabilitation Nursing: A Core Curriculum, 7th Edition. The Core Curriculum serves as the foundation for the rehabilitation nursing profession and can be applied to the many diverse settings and roles, including acute rehabilitation, post-acute care, community settings, skilled nursing homes, case management, research facilities, consulting academia, and clinics.
The problem with cancer treatments designed to kill a tumor is that they can kill the patient's quality of life as well. Now a Florida State University College of Medicine researcher is shifting the focus from eradicating brain tumors to managing them.
Data results published this month in Clinical Neuropharmacology, revealed that Merz Pharmaceuticals' NT 201 (botulinum toxin type A free from complexing proteins), also known by the brand name Xeomin in Europe and Canada, was statistically significantly more efficacious than placebo for the treatment of patients with post-stroke upper limb spasticity.
Addus HomeCare Corporation, a comprehensive provider of home-based social and medical services, announced today the award of three new contracts that broaden its presence in the growing Southeast market.
HeartWare International, Inc., a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced that the U.S. Food and Drug Administration (FDA) has approved an IDE (Investigational Device Exemption) Supplement that allows HeartWare to enroll a second allotment of 54 patients in its "ADVANCE" bridge-to-transplant clinical trial under a Continued Access Protocol (CAP).
› Verified 4 days ago